Literature DB >> 29550966

Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR.

David E Kaplan1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29550966      PMCID： PMC5955839          DOI： 10.1007/s10620-018-5014-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  10 in total

1.  Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.

Authors:  Salvatore Petta; Giuseppe Cabibbo; Marco Enea; Fabio Salvatore Macaluso; Antonella Plaia; Raffaele Bruno; Antonio Gasbarrini; Savino Bruno; Antonio Craxì; Calogero Cammà
Journal:  Dig Liver Dis       Date:  2014-07-23       Impact factor: 4.088

2.  The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting.

Authors:  M Michele Manos; Jeanne Darbinian; Jaime Rubin; G Thomas Ray; Valentina Shvachko; Baris Denis; Fulton Velez; Charles Quesenberry
Journal:  J Manag Care Pharm       Date:  2013 Jul-Aug

3.  Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.

Authors:  Z M Younossi; H Park; S Saab; A Ahmed; D Dieterich; S C Gordon
Journal:  Aliment Pharmacol Ther       Date:  2015-01-26       Impact factor: 8.171

4.  Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Authors:  Jagpreet Chhatwal; Shannon A Ferrante; Cliff Brass; Antoine C El Khoury; Margaret Burroughs; Bruce Bacon; Rafael Esteban-Mur; Elamin H Elbasha
Journal:  Value Health       Date:  2013 Sep-Oct       Impact factor: 5.725

5.  Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

Authors:  Calogero Cammà; Salvatore Petta; Giuseppe Cabibbo; Matteo Ruggeri; Marco Enea; Raffaele Bruno; Vincenza Capursi; Antonio Gasbarrini; Alfredo Alberti; Antonio Craxì
Journal:  J Hepatol       Date:  2013-05-23       Impact factor: 25.083

Review 6.  Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.

Authors:  Jagpreet Chhatwal; Tianhua He; Chin Hur; Maria A Lopez-Olivo
Journal:  Clin Gastroenterol Hepatol       Date:  2016-09-17       Impact factor: 11.382

7.  Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.

Authors:  Marissa M Maier; Xiao-Hua Zhou; Michael Chapko; Steven L Leipertz; Xuan Wang; Lauren A Beste
Journal:  Dig Dis Sci       Date:  2018-02-16       Impact factor: 3.199

8.  Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease.

Authors:  S C Gordon; F M Hamzeh; P J Pockros; R S Hoop; A R Buikema; E J Korner; N A Terrault
Journal:  Aliment Pharmacol Ther       Date:  2013-08-25       Impact factor: 8.171

9.  Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.

Authors:  Zobair M Younossi; Mendel E Singer; Heshaam M Mir; Linda Henry; Sharon Hunt
Journal:  J Hepatol       Date:  2013-11-19       Impact factor: 25.083

10.  The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics.

Authors:  David B Rein; Joshua Borton; Danielle K Liffmann; John S Wittenborn
Journal:  Hepatology       Date:  2016-02-26       Impact factor: 17.425
  10 in total
  1 in total

1.  Treating the Hardest to Treat: Reframing the Hospital Admission as an Opportunity to Initiate Hepatitis C Treatment.

Authors:  Elizabeth Le; Grace Chee; Miki Kwan; Ramsey Cheung
Journal:  Dig Dis Sci       Date:  2021-03-26       Impact factor: 3.199
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.